André Rancourt

André Rancourt discloses dealings in Tetra Bio-Pharma Inc. to SEDI. We count 14 filings; the first trade dates from 19 September 2016 and the latest from 19 March 2018.

Both buying and selling appear: 2 purchases worth €7,417, against 5 sales worth €229k. Sales outweigh purchases by €222k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 4 option exercises.

The newest entry dates from 19 March 2018: a transaction, in Tetra Bio-Pharma Inc. The most recent open-market purchase was published on 13 April 2017, 3,485 days ago. Between a trade and the moment it shows up on SEDI, the median delay is 2 days. This delay matters because a trade only becomes useful information once it is public. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEDI disclosures alone and does not predict where the share price will go.